Executive Severance Benefits AgreementExecutive Severance Benefits Agreement • February 27th, 2018 • Five Prime Therapeutics Inc • Pharmaceutical preparations • California
This Executive Severance Benefits Agreement (this “Agreement”), effective as of March 20, 2017 (the “Effective Date”), is between Helen Collins (“Executive”) and Five Prime Therapeutics, Inc. (“FivePrime”). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • February 27th, 2018 • Five Prime Therapeutics Inc • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made as of December 19, 2017 (the “Effective Date”), by and between Five Prime Therapeutics, Inc., a Delaware corporation (“Five Prime”), having a place of business at 111 Oyster Point Boulevard, South San Francisco, California 94080, USA, and Zai Lab (Shanghai) Co., Ltd., a limited company organized under the laws of P.R. of China (“Zai”), having a place of business at 4560 Jinke Rd, Bldg. 1, 4/F, Pudong, Shanghai, China, 201210. Five Prime and Zai are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
Amendment No. 2 to Exclusive License AgreementExclusive License Agreement • February 27th, 2018 • Five Prime Therapeutics Inc • Pharmaceutical preparations
This Amendment No. 2 to Exclusive License Agreement (this “Amendment”), effective May 30, 2017 (the “Amendment Effective Date”), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (“FivePrime”), and Galaxy Biotech, LLC, a Delaware limited liability company (“Galaxy”).
